

Contents

List of Participants	1
Preamble	3
General Remarks	15
1. Introduction	15
1.1 Observational studies of colorectal cancer	16
1.2 Studies in experimental animals	16
1.3 Drugs considered	16
2. Colorectal cancer	16
2.1 Descriptive epidemiology	16
2.2 Biology of colorectal cancer in humans	16
2.3 Experimental studies	17
3. Pharmacological action of non-steroidal anti-inflammatory drugs	19
3.1 Synthesis and action of prostaglandins	19
3.2 Prostaglandins and human tumours	20
3.3 Alternative mechanisms	23
3.3.1 <i>Mechanisms independent of prostaglandins</i>	23
3.3.2 <i>Effects of non-cancerous tissues</i>	23
3.3.3 <i>Cytochrome P450</i>	24
4. Adverse effects	24
4.1 Ulceration	25
4.1.1 <i>Age</i>	25
4.1.2 <i>History of ulcer disease</i>	25
4.1.3 <i>Helicobacter pylori</i>	26
4.1.4 <i>Corticosteroids</i>	26
4.1.5 <i>Anticoagulants</i>	26
4.2 Asthma	26
4.3 Drug interactions	26
4.4 Taking account of toxic effects	27
4.5 Mitigating side-effects	27
5. Recommendations for research	28
6. Procedures used	29
7. References	29

Aspirin

1.	Chemical and physical characteristics	43
1.1	Name	43
1.2	Structural and molecular formulae and relative molecular mass	43
1.3	Physical and chemical properties	43
1.4	Technical products	43
2.	Occurrence, production, use, analysis and human exposure	44
2.1	Occurrence	44
2.2	Production	44
2.3	Use	44
2.4	Analysis	44
2.5	Human exposure	45
3.	Metabolism, kinetics and genetic variation	46
3.1	Human studies	46
3.1.1	<i>Metabolism</i>	46
3.1.2	<i>Pharmacokinetics</i>	47
3.2	Experimental models	50
3.3	Genetic variation	50
4.	Cancer-preventive effects	50
4.1	Human studies	50
4.1.1	<i>Studies of colorectal cancer</i>	50
4.1.2	<i>Studies of sporadic adenomatous polyps in the colon</i>	58
4.1.3	<i>Studies of oesophageal and gastric cancers</i>	60
4.1.4	<i>Studies of cancers other than in the digestive tract</i>	62
4.1.5	<i>Issues in interpreting the evidence for prevention of colorectal cancer</i>	63
4.2	Experimental models	64
4.2.1	<i>Experimental animals</i>	64
4.2.2	<i>In-vitro models</i>	67
4.3	Mechanisms of chemoprevention	67
4.3.1	<i>Inhibition of carcinogen activation</i>	67
4.3.2	<i>Inhibition of cell proliferation</i>	68
4.3.3	<i>Apoptosis</i>	68
4.3.4	<i>Immune surveillance</i>	68
5.	Other beneficial effects	70
5.1	Antiplatelet effects	70
5.1.1	<i>Background</i>	70
5.1.2	<i>Mechanism</i>	70
5.1.3	<i>Secondary prevention in populations at high risk for cardiovascular events</i>	70
5.1.4	<i>Primary prevention in populations at average risk for cardiovascular events</i>	71
5.1.5	<i>Lowest effective dose for prevention of cardiovascular events in high-risk populations</i>	71
5.2	Alzheimer disease	71
5.3	Reproductive outcomes	71

6.	Carcinogenicity	72
6.1	Human studies	72
6.1.1	<i>Renal cancer</i>	72
6.1.2	<i>Haematopoietic malignancies</i>	73
6.1.3	<i>Childhood cancer</i>	73
6.2	Experimental animals	73
7.	Other toxic effects	73
7.1	Adverse effects	73
7.1.1	<i>Humans</i>	73
7.1.2	<i>Experimental animals</i>	81
7.2	Genetic and related effects	84
7.2.1	<i>Humans</i>	84
7.2.2	<i>Experimental models</i>	84
8.	Summary of data	87
8.1	Chemistry, occurrence and human exposure	87
8.2	Metabolism and kinetics	87
8.3	Cancer-preventive effects	87
8.3.1	<i>Humans</i>	87
8.3.2	<i>Experimental animals</i>	88
8.3.3	<i>Mechanism of action</i>	88
8.4	Other beneficial effects	88
8.5	Carcinogenicity	88
8.5.1	<i>Humans</i>	88
8.5.2	<i>Experimental animals</i>	88
8.6	Toxic effects	88
8.6.1	<i>Humans</i>	88
8.6.2	<i>Experimental animals</i>	89
9.	Recommendations for research	89
10.	Evaluation	90
10.1	Cancer-preventive activity	90
10.1.1	<i>Humans</i>	90
10.1.2	<i>Experimental animals</i>	90
10.2	Overall evaluation	90
11.	References	90

Sulindac 103

1.	Chemical and physical characteristics	103
1.1	Name	103
1.2	Structural and molecular formulae and relative molecular mass	103
1.3	Physical and chemical properties	103
1.4	Technical products	103

2.	Occurrence, production, use, analysis and human exposure	103
2.1	Occurrence	103
2.2	Production	103
2.3	Use	104
2.4	Analysis	104
2.5	Human exposure	104
3.	Metabolism, kinetics and genetic variation	104
3.1	Human studies	104
3.1.1	<i>Metabolism</i>	104
3.1.2	<i>Pharmacokinetics</i>	104
3.2	Experimental models	105
3.3	Genetic variation	106
4.	Cancer-preventive effects	106
4.1	Human studies	106
4.1.1	<i>Studies of adenomatous polyps in patients with familial adenomatous polyposis</i>	106
4.1.2	<i>Randomized clinical trial of sporadic adenomatous polyps</i>	108
4.1.3	<i>Case studies of treatment for desmoid tumours</i>	108
4.2	Experimental models	108
4.2.1	<i>Experimental animals</i>	108
4.2.2	<i>In-vitro models</i>	114
4.3	Mechanisms of chemoprevention	114
4.3.1	<i>Effects on cell proliferation and apoptosis</i>	114
4.3.2	<i>Effects on oncogene expression</i>	115
5.	Other beneficial effects	115
6.	Carcinogenicity	115
6.1	Humans	115
6.2	Experimental animals	115
7.	Other toxic effects	115
7.1	Adverse effects	115
7.1.1	<i>Humans</i>	115
7.1.2	<i>Experimental animals</i>	117
7.2	Genetic and related effects	117
8.	Summary of data	117
8.1	Chemistry, occurrence and human exposure	117
8.2	Metabolism and kinetics	118
8.3	Cancer-preventive effects	118
8.3.1	<i>Humans</i>	118
8.3.2	<i>Experimental animals</i>	118
8.3.3	<i>Mechanism of action</i>	118
8.4	Other beneficial effects	118
8.5	Carcinogenicity	118
8.6	Toxic effects	118
8.6.1	<i>Humans</i>	118
8.6.2	<i>Experimental animals</i>	118
9.	Recommendations for research	118

10.	Evaluation	119
10.1	Cancer-preventive activity	119
10.1.1	<i>Humans</i>	119
10.1.2	<i>Experimental animals</i>	119
10.2	Overall evaluation	119
11.	References	119

Piroxicam 127

1.	Chemical and physical characteristics	127
1.1	Name	127
1.2	Structural and molecular formulae and relative molecular mass	127
1.3	Physical and chemical properties	127
1.4	Technical products	127
2.	Occurrence, production, use, analysis and human exposure	127
2.1	Occurrence	127
2.2	Production	127
2.3	Use	127
2.4	Analysis	128
2.5	Human exposure	128
3.	Metabolism, kinetics and genetic variation	128
3.1	Human studies	128
3.1.1	<i>Metabolism</i>	128
3.1.2	<i>Pharmacokinetics</i>	128
3.2	Experimental models	132
3.2.1	<i>Metabolism</i>	132
3.2.2	<i>Pharmacokinetics</i>	132
3.3	Genetic variation	133
4.	Cancer-preventive effects	133
4.1	Human studies	133
4.2	Experimental models	134
4.2.1	<i>Experimental animals</i>	134
4.2.2	<i>In-vitro models</i>	138
4.3	Mechanisms of chemoprevention	139
4.3.1	<i>Preneoplastic lesions</i>	139
4.3.2	<i>Inhibition of carcinogen activation</i>	139
4.3.3	<i>Effects on cell proliferation and apoptosis</i>	140
4.3.4	<i>Immune surveillance</i>	140
5.	Other beneficial effects	141
6.	Carcinogenicity	141
6.1	Humans	141
6.2	Experimental animals	141

7.	Other toxic effects	141
7.1	Adverse effects	141
7.1.1	<i>Humans</i>	141
7.1.2	<i>Experimental animals</i>	141
7.2	Genetic and related effects	142
7.2.1	<i>Humans</i>	142
7.2.2	<i>Experimental models</i>	142
8.	Summary of data	143
8.1	Chemistry, occurrence and human exposure	143
8.2	Metabolism and kinetics	143
8.3	Cancer-preventive effects	143
8.3.1	<i>Humans</i>	143
8.3.2	<i>Experimental animals</i>	143
8.3.3	<i>Mechanism of action</i>	143
8.4	Other beneficial effects	143
8.5	Carcinogenicity	143
8.6	Toxic effects	143
8.6.1	<i>Humans</i>	143
8.6.2	<i>Experimental animals</i>	143
9.	Recommendations for research	143
10.	Evaluation	144
10.1	Cancer-preventive activity	144
10.1.1	<i>Humans</i>	144
10.1.2	<i>Experimental animals</i>	144
10.2	Overall evaluation	144
11.	References	144
Indomethacin		151

1.	Chemical and physical characteristics	151
1.1	Name	151
1.2	Structural and molecular formulae and relative molecular mass	151
1.3	Physical and chemical properties	151
1.4	Technical products	151
2.	Occurrence, production, use, analysis and human exposure	151
2.1	Occurrence	151
2.2	Production	151
2.3	Use	152
2.4	Analysis	152
2.5	Human exposure	152

3.	Metabolism, kinetics and genetic variation	152
3.1	Human studies	152
3.1.1	<i>Metabolism</i>	152
3.1.2	<i>Pharmacokinetics</i>	152
3.2	Experimental models	156
3.3	Genetic variation	157
4.	Cancer-preventive effects	157
4.1	Human studies	157
4.1.1	<i>Studies of cancer occurrence</i>	157
4.1.2	<i>Studies of other relevant end-points</i>	158
4.2	Experimental models	158
4.2.1	<i>Experimental animals</i>	158
4.2.2	<i>In-vitro models</i>	171
4.3	Mechanisms of chemoprevention	172
4.3.1	<i>Inhibition of carcinogen activation</i>	172
4.3.2	<i>Effects on cell proliferation and apoptosis</i>	172
4.3.3	<i>Immune surveillance</i>	175
5.	Other beneficial effects	176
6.	Carcinogenicity	176
6.1	Humans	176
6.2	Experimental animals	176
7.	Other toxic effects	177
7.1	Adverse effects	177
7.1.1	<i>Humans</i>	177
7.1.2	<i>Experimental animals</i>	178
7.2	Genetic and related effects	183
7.2.1	<i>Humans</i>	183
7.2.2	<i>Experimental models</i>	183
8.	Summary of data	184
8.1	Chemistry, occurrence and human exposure	184
8.2	Metabolism and kinetics	184
8.3	Cancer-preventive effects	184
8.3.1	<i>Humans</i>	184
8.3.2	<i>Experimental animals</i>	184
8.3.3	<i>Mechanism of action</i>	184
8.4	Other beneficial effects	184
8.5	Carcinogenicity	184
8.5.1	<i>Humans</i>	184
8.5.2	<i>Experimental animals</i>	184
8.6	Toxic effects	184
8.6.1	<i>Humans</i>	184
8.6.2	<i>Experimental animals</i>	185
9.	Recommendations for research	185

10.	Evaluation	185
10.1	Cancer-preventive activity	185
10.1.1	<i>Humans</i>	185
10.1.2	<i>Experimental models</i>	185
10.2	Overall evaluation	185
11.	References	185
Appendix 1. The concept of activity profiles of antimutagens		199
Appendix 2. Definitions of test codes		202